Furthermore, HDAC6 inhibitor treatment restored defective primary cilia, tubulin acetylation, and abnormal mitochondrial distribution in NEK1 LOF patient-derived fibroblasts and iPSC-MNs model, suggesting its potential as a therapeutic target for ALS. Here, HDAC6 is linked to amyotrophic lateral sclerosis.